top of page
Browse by category
Search


Research animation explores first-hand experiences of receiving online support for eating disorders
During the COVID-19 pandemic, many healthcare services were transitioned to run remotely - for example via video calls - creating...


New framework for diagnosing obesity based on body fat distribution not BMI
A new framework for the diagnosis, staging and management of obesity in adults, launched by the European Association for the Study of...

Zhejiang Doer Biologics completes enrolment of the Phase 1b/2a trial evaluating DR10624 in people with obesity with modest hypertriglyceridemia
Zhejiang Doer Biologics has completed the enrolment in the Phase 1b/2a trial evaluating DR10624 in people with obesity with modest...

Semaglutide linked to uncommon blindness condition NAION
Patients prescribed semaglutide (as Ozempic or Wegovy) for diabetes or weight loss had a higher risk of having a potentially blinding eye...

Journal Watch 3/07/2024
Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...


Lab values predict periprosthetic joint infection in patients living with severe obesity
For patients with severe obesity undergoing knee or hip replacement, commonly obtained laboratory values - including markers of anaemia...

GSA publishes recommendations for the successful care of older adults with obesity
A summit convened by the Gerontological Society of America (GSA) has resulted in the identification of seven strategies for successful...


US Task Force recommends intensive, comprehensive behavioural interventions for children and teens with a high BMI
The US Preventive Services Task Force (Task Force) has posted a final recommendation statement on interventions for high body mass index...


OAC welcomes House Committee decision for advancing the Treat and Reduce Obesity Act
The Obesity Action Coalition (OAC) has welcomed the House Ways and Means Committee for favourably reporting an amended version of the...


First patient dosed NeuroBo Pharmaceuticals’ Phase 1 clinical trial evaluating DA-1726 for the treatment of obesity
NeuroBo Pharmaceuticals has dosed the first patient in the multiple ascending dose (MAD) Part 2 of its Phase 1 clinical trial of DA-1726,...
Browse by tag






bottom of page